Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA’s approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018. We have

Continue reading

Technology Landscape Study on CRISPR-Cas9

Although CRISPR was known to have an important role in bacterial immunity for over a decade, it is only in the last 5 years that it has garnered interest as a gene editing tool. Increasing investment in this field is indicative of global market opportunities for CRISPR-Cas9 over existing alternatives. The objective of this study is to explore the market and patenting activity in CRISPR-Cas9 gene editing technology. This study considers issued patents and pending published applications related to CRISPR-Cas9 published since January 1, 2007. Search strategies using various combinations of keywords, classification codes, and prominent assignees resulted in more

Continue reading

MaxVal to Sponsor and Exhibit at IPBC Global, San Francisco (June 10-12, 2018)

MaxVal is sponsoring the 11th annual event of IP Business Congress Global (IPBC), to be held from June 10-12, 2018 at Palace Hotel, San Francisco. IPBC is an established gathering for the World’s IP Business leaders ensuring extensive formal and informal networking opportunities. Its unrivaled coverage and in-depth analysis of key sectors provide executives critical business intelligence to maximize the IP value. As an exhibiting sponsor, MaxVal will demonstrate its end-to-end IP Management platform, Symphony, known for its robustness, reliability, and automation in handling the complete IP lifecycle. “I’m proud to be a part of the company that has created Symphony

Continue reading

Recent advances in Diabetes Management | April 2018 Newsletter | MaxVal

The article addresses Medtronic’s recent FDA approval of the Guardian™ Connect Continuous Glucose Monitoring (CGM) system. A brief overview of all the clinical studies related to CGM has been presented. It also analyzes the recent findings on a microneedle system for non-invasive insulin delivery. A birds-eye view of patent filings related to microneedles for insulin delivery, with a focus on global players is presented.

Continue reading

MaxVal Exhibits at INTA 140th Annual Meeting, Seattle, WA (May 19-23, 2018)

MaxVal is exhibiting at INTA 140th Annual meeting at Booth #418, to be held from May 19-23 at Washington State Convention Center, Seattle, WA. INTA’s (International Trademark Association) Annual Meeting is recognized as one of the premier events for the trademark industry which is expected to attract more than 10,000 attendees from around the world. Brand owners, in-house counsel, law firms, government officials, and other IP experts will gather in this 140th annual meeting to discuss and examine the key industry issues, challenges, and opportunities in the ever-growing IP landscape. MaxVal, a preferred IP management partner for law firms and

Continue reading